Douglas Ingram, JD

Douglas S. Ingram was appointed Sarepta’s President, Chief Executive Officer and a member of the Board in June 2017. Since that time, Mr. Ingram and his team set out to make Sarepta the leader in the use of genetic medicine – RNA, gene therapy and gene editing – to treat rare disease, including treatments for Duchenne muscular dystrophy and limb-girdle muscular dystrophies, as well as other rare neuromuscular, neurological and cardiomyopathic diseases. Since joining Sarepta, Mr. Ingram has led the Company through significant growth, including building a 40+ candidate portfolio of programs spanning RNA, gene therapy and gene editing, launching, and driving the uptake of three RNA therapies, as well as the approval and launch of the first gene therapy to treat Duchenne. Since Mr. Ingram’s appointment, Sarepta has achieved compounded annual revenue growth of approximately 40% as it has matured into a profitable, cash flow positive organization. Since 2017, Sarepta has reshaped the genetic medicine landscape, executing over 50 strategic partnerships with world leading scientists and organizations to advance programs and improve the delivery, safety, and effectiveness of genetic medicine. Under Mr. Ingram’s leadership, Sarepta has grown from approximately 250 employees in 2017 to over 1,300 employees worldwide in 2024, building first-in-class expertise in all aspects of DNA and mRNA targeted therapy, including research, development, technical operations, medical affairs, commercial, and access and reimbursement.

Mr. Ingram’s career in healthcare spans over two decades. As the former President and a member of the executive team for Allergan, a global pharmaceutical leader, he played an instrumental role in driving the Company’s growth trajectory from 1996 through early 2015, when it was acquired by Actavis. Following Allergan, from December 2015 until November 2016 when it was sold, Mr. Ingram served as the President, Chief Executive Officer, and a Director of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on neurodegenerative disorders. Prior to joining Allergan, he began his legal career as an Associate at the law firm Gibson, Dunn & Crutcher LLP.

Mr. Ingram currently serves on the Board of Directors for Relay Therapeutics. He graduated magna cum laude from Arizona State University with a Bachelor of Science degree and summa cum laude from the University of Arizona, James E. Rogers College of Law.